Cost Utility of Prasugrel in Postangioplasty Diabetic Patients

•Prasugrel is an effective drug for the reduction of myocardial infarction and stent thrombosis in the postangioplasty scenario, although its safety profile is limited regarding hemorrhagic events.•Our model adds new information regarding its cost-utility in comparison with clopidogrel in the perspective of the Brazilian National Health System, for diabetic patients.•Despite the lack of threshold in Brazil, this study presents promising cost-utility for the use of prasugrel in specific conditions. Its approval should remain on the balance between safety and efficacy profiles and may be better indicated for patients with a low risk of hemorrhagic events.